Thiamine and estimated glomerular filtration rate in type 2 diabetes with chronic kidney disease stage 3: A pragmatic randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200215004

Enrollment

Registered

2020-02-15

Start date

2017-07-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Function: estimated glomerular filtration rate change between group Thiamine estimated glomerular filtration rate type 2 diabetes chronic kidney disease stage 3

Interventions

Case group receive thiamine 2 Capsules after breakfast (150 mg/capsules

300 mg once daily) for 24 weeks ,Case group receive Placebo 2 capsules after breakfast for 24 weeks

Active Comparator Drug,Placebo Comparator Drug

Thiamine(VitaminB1),Placebo

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: Type 2 Diabetes with chronic kidney disease stage 3

Exclusion criteria

Exclusion criteria: 1.History of Thiamine allergy 2.History of cardiovascular disease 3.History of Kidney stone 4.History of kidney surgery

Design outcomes

Primary

Measure	Time frame
Kidney Function between group at 6 months after end of the intervention estimated glomerular filtration rate (eGFR) change between group	—

Secondary

Measure	Time frame
Kidney Function within group at 6 months after end of the intervention 1.eGFR change within group ,Diabetes control between group at 6 months after end of the intervention Hb A1C change between group,Lipid level between group at 6 months after end of the intervention Cholesterol,LDL,HDL and triglyceride change between group, Urine microalbumine between group at 6 months after end of the intervention Urine microalbumine change between group,Adverse events and serious events at 6 months after end of the intervention Adverse events and serious events	—

Measure

Time frame

Kidney Function within group at 6 months after end of the intervention 1.eGFR change within group ,Diabetes control between group at 6 months after end of the intervention Hb A1C change between group,Lipid level between group at 6 months after end of the intervention Cholesterol,LDL,HDL and triglyceride change between group, Urine microalbumine between group at 6 months after end of the intervention Urine microalbumine change between group,Adverse events and serious events at 6 months after end of the intervention Adverse events and serious events

—

Countries

Thailand

Contacts

Public ContactSirilakkhana Phrawong

KhonKaenHospital

Phiris_y@hotmail.com0880113065

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026